This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Rigel J Kishton: Innovator in T Cell Production
Introduction
Rigel J Kishton is a notable inventor based in Columbia, MD (US). He has made significant contributions to the field of immunology, particularly in the production of T cell populations. His innovative methods have the potential to impact cancer treatment and prevention.
Latest Patents
Kishton holds a patent for "Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof." This patent outlines methods for producing an isolated population of T cells by culturing them in vitro with hydroxycitric acid or its salts, such as potassium hydroxycitrate or sodium hydroxycitrate. The patent also includes related isolated populations of cells, pharmaceutical compositions, and methods for treating or preventing cancer in mammals. He has 1 patent to his name.
Career Highlights
Kishton works for the United States of America, as represented by the Secretary, Department of Health and Human Services. His role in this esteemed organization highlights his commitment to advancing health and medical research.
Collaborations
Kishton has collaborated with notable colleagues, including Nicholas P Restifo and Suman Kumar Vodnala. These partnerships have likely contributed to the success of his research and innovations.
Conclusion
Rigel J Kishton is a prominent figure in the field of T cell research, with a focus on innovative methods that could revolutionize cancer treatment. His work exemplifies the intersection of science and innovation, paving the way for future advancements in immunotherapy.